A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure platelets, and endothelium function in patients with essential hypertension

Japanese Heart Journal

Volumn 45, Issue 4, 2004, Pages 623-635

  Leu, Hsin Bang ^a   Charng, Ming Ji ^a   Ding, Philip Yu An ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Angiotensin receptor antagonist; Beta thromboglobulin( TG); Platelet factor 4(PF4); Venous occlusive plethysmography; von Willebrand factor (vWF)

Indexed keywords

BETA THROMBOGLOBULIN; ENALAPRIL; EPROSARTAN; THROMBOCYTE FACTOR 4; VON WILLEBRAND FACTOR; ACRYLIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; VEIN OCCLUSION PLETHYSMOGRAPHY; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG EFFECT; HYPERTENSION; MIDDLE AGED; PROSPECTIVE STUDY; VASCULAR ENDOTHELIUM;

ACRYLATES; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ENALAPRIL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PLATELET ACTIVATION; PROSPECTIVE STUDIES; THIOPHENES;

EID: 6344252861     PISSN: 00214868     EISSN: 1348673X     Source Type: Journal    
DOI: 10.1536/jhj.45.623     Document Type: Article

References (30)

1. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
2. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821-8.
3. Remme WJ. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy? Drugs 1997; 54 Suppl 5: 59-70.
4. Henrion D, Dechaux E, Dowell FJ, et al. Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2. Br J Pharmacol 1997; 121: 83-90.
5. Oshima S, Ogawa H, Mizuno Y, et al. The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Am Heart J 1997; 134: 961-6.
6. Strawn WB, Ferrario CM. Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol 2002; 13: 505-12.
7. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998; 83: 952-9.
8. Tummala PE, Chen XL, Sundell CL, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999; 100: 1223-9.
9. Ferrario CM. Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens 2002; 15: 9S-13S.
10. Gomi T, Ikeda T, Yuhara M, Sakurai J, Nakayama D, Ikegami F. Plasma beta-thromboglobulin to platelet factor 4 ratios as indices of vascular complications in essential hypertension. J Hypertens 1988; 6: 389-92.
11. Ding YA, Chou TC, Lin KC. Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension. J Hum Hypertens 1994; 8: 273-8.
12. Blann AD, Naqvi T, Waite M, McCollum CN. von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7: 107-11.
13. Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY. von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2002; 40: 61-6.
14. Wu HD, Katz SD, Beniaminovitz A, Khan T, DiTullio MR, Homma S. Assessment of endothelium-mediated vasodilation of the peripheral circulation by transcutaneous ultrasonography and venous occlusion plethysmography. Heart Vessels 1999; 14: 143-8.
15. Endo T, Imaizumi T, Tagawa T, Shiramoto M, Ando S, Takeshita A. Role of nitric oxide in exercise-induced vasodilation of the forearm. Circulation 1994; 90: 2886-90.
16. Levine B. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension. Curr Med Res Opin 2001; 17: 8-17.
17. Bohm M, Sachse A. Safety and tolerability of eprosartan in combination with hydrochlorothiazide. Drug Saf 2002; 25: 599-611.
18. Rake EC, Breeze E, Fletcher AE. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo. J Hum Hypertens 2001; 15: 863-7.
19. Piqueras L, Kubes P, Alvarez A, et al. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation 2000; 102: 2118-23.
20. Hope S, Brecher P, Chobanian AV. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens 1999; 12: 28-34.
21. Ambrosioni E, Bacchelli S, Esposti DD, Borghi C. Anti-ischemic effects of angiotensin-converting enzyme inhibitors: a future therapeutic perspective. J Cardiovasc Pharmacol 2001; 37 Suppl 1: S3-S9.
22. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 2000; 11: 61-9.
23. Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202.
24. Goodfield NE, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-5.
25. Nunez A, Gomez J, Zalba LR, et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 2000; 1: 175-9.
26. Monton M, Jimenez A, Nunez A, et al. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000; 35: 906-13.
27. Li-Saw-Hee FL, Beevers DG, Lip GY. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int J Cardiol 2001; 78: 241-6.
28. Blann AD, Lip GY, Islim IF, Beevers DG. Evidence of platelet activation in hypertension. J Hum Hypertens 1997; 11: 607-9.
29. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-65.
30. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35: 60-6.